Trending

    Everest Group Life Sciences Digital Services Specialists PEAK Matrix® Assessment 2024

    We’re proud to have been named a Leader in the Everest Group Life Sciences Digital Services Specialists PEAK Matrix® Report. Everest Group classified ...

    Learn More
    From Chaos to Cohesion
    Politics ‘Trumps’ Rational Policy Rule Change On Ending Rebates To PBMs For The Medicare Program

    Politics ‘Trumps’ Rational Policy Rule Change On Ending Rebates To PBMs For The Medicare Program

    The Trump administration announced earlier this year a proposal to eliminate rebates to PBMs in the Medicare and parts of the Medicaid programs effective January 1, 2020. The Trump administration made eliminating rebates a significant part of the American Patients First blueprint initiative launched in May 2018 to reduce out-of-pocket prescription drug costs. Most pharma experts predicted this ...
    Learn More
    Has Traditional Call Planning Passed Its Prime?

    Has Traditional Call Planning Passed Its Prime?

    The short answer to this question is most definitely “yes,” and probably more important now than ever before. Annual pharma company spending on their sales force is still among the single largest line item in the budget, and according to promotion-response and marketing-mix analyses, remains a significant driver of sales revenue and contribution. The changes in the pharma environment from a ...
    Learn More
    Proposed Rule To End Rebates To PBMs For Medicare And Medicaid Programs: What Does This Mean For Pharma Companies?

    Proposed Rule To End Rebates To PBMs For Medicare And Medicaid Programs: What Does This Mean For Pharma Companies?

    Alex Azar, Secretary of Health and Human Services (HHS), made a significant game-changing announcement to prescription drug pricing during the federal government shutdown that received little attention in the popular press. In short, the proposed rule would eliminate rebates to pharmacy benefit managers (PBMs) in the Medicare and Medicaid programs by January 1, 2020. This change from the Trump ...
    Learn More
    Perspectives On Pharma Company Use Of Open Payments Data

    Perspectives On Pharma Company Use Of Open Payments Data

    The creation of Open Payments Data (OPD) was formed from the Affordable Care Act to bring greater public transparency to the financial relationships between pharma and medical device companies, and healthcare providers. This white paper provides a detailed analysis on the role and effects of “Sunshine Laws” and payments made to providers as seen from published empirical evidence, intricacies, and ...
    Learn More
    Challenges And Opportunities To Commercialize Orphan Drugs For Rare Diseases In The US

    Challenges And Opportunities To Commercialize Orphan Drugs For Rare Diseases In The US

    Orphan drugs (ODs) for rare diseases (RDs) present pharma companies with the opportunity to address a substantial unmet medical need, with approximately 7,000 RDs and only about 5% having effective treatments. A large number of patients in the US are affected by these RDs (around 25-30 million people). The majority of RDs affect children. Also, RDs often translate into chronic and deteriorating ...
    Learn More
    Growing Attention Being Paid To Pharma Company Rebates And Discounts

    Growing Attention Being Paid To Pharma Company Rebates And Discounts

    Drug company rebates and discounts have always been an opaque aspect of the US pharma industry. There is little transparency in how much drug companies pay in rebates and discounts. Indications are it is annually in the tens of billions of dollars for the industry and growing. Price concessions can significantly vary by individual company depending on the portfolio mix and individual therapy ...
    Learn More
    How Will The 2018 Midterm Congressional Election Results Affect The US Pharma Industry?

    How Will The 2018 Midterm Congressional Election Results Affect The US Pharma Industry?

    The 2018 Congressional midterm elections are over after a bitter political fight. The voters have spoken. We are back to divided government, with Democrats controlling the House, and Republicans expanding their majority in the Senate. Will there be bipartisan collaboration or political conflict and policy immobilism? This paper provides a detailed analysis why the US pharma industry, specifically ...
    Learn More
    Is The CVS-Aetna Merger A Pharma Industry Transformative Event?

    Is The CVS-Aetna Merger A Pharma Industry Transformative Event?

    US antitrust officials recently approved the proposed $69 billion CVS-Aetna merger. This merger follows a similar action taken by the Justice Department to approve the Cigna-Express Scripts merger, and partnering activities by Amazon, Berkshire Hathaway, and J.P. Morgan to get into the healthcare industry. These events taken together suggest what some have characterized as “the era of retail ...
    Learn More
    Deploying Successful Global Incentive Compensation Capabilities

    Deploying Successful Global Incentive Compensation Capabilities

    Companies spend between 10% and 40% of their total revenue on their sales force - Bain, Frontline of Healthcare Report Over 70% organizations feel their employees do not understand the compensation philosophy - workatwork.org Incentive Compensation (IC) can single-handedly make or break your sales force. It’s a process that sales and commercial leaders constantly strive to get right and implement ...
    Learn More